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Background: The Glasgow Prognostic Score (GPS) measures inflammation and proves its prognostic value in
patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL) which is commonly combined with
inflammatory lesion. Given inflammatory chemokines play an important role in tumor progression, we hypothesized
that chemokines might influence ENKTL aggressiveness through interaction with their receptors in the tumor tissue.
Methods: We measured the serum levels of C-X-C motif ligand 13 (CXCL13) in 69 patients with ENKTL who received
non-anthracycline-based chemotherapy and/or concurrent chemoradiotherapy because CXCL13 is thought to have a
pro-tumor effect through interaction with its receptor, the C-X-C chemokine receptor 5 (CXCR5). We analyzed the
association of serum CXCL13 with the GPS, and their prognostic relevance. The levels of CXCL13 were measured using
a multiplex chemokine assay on archived frozen serum samples.
Results: Patients were categorized into high and low CXCL13 groups if they had CXCL13 levels above or below the
median value of 29.1 pg/mL, respectively. The high CXCL13 group and grouping by the GPS showed a significant
association with poor progression-free survival. The elevated serum levels of CXCL13 were also significantly associated
with a high score of the GPS. High CXCL13 levels and GPS were significantly associated with high tumor burden
predicting poor prognosis including stages III/IV, extranasal presentation, bone marrow invasion, and presence of
Epstein-Barr virus (EBV) DNA in blood. Furthermore, serum CXCL13 and GPS discriminated patients at risk of treatment
failure among patients with low tumor burden (stage I/II) and non-detectable EBV DNA.
Conclusions: Serum levels of CXCL13 were associated with the prognostic value of GPS. Grouping by the serum
CXCL13 might predict survival outcomes in patients with ENKTL, suggesting that it is a potential therapeutic target.
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Extranodal natural killer (NK)/T-cell lymphoma (ENKTL)
is a subtype of non-Hodgkin lymphoma (NHL), and
ENKTL is strongly associated with latent Epstein-Barr virus
(EBV) infection and usually shows aggressive behavior with
a poor prognosis [1]. Although chemoradiotherapy and
non-anthracycline-based chemotherapy have been shown
to improve outcome [2,3], treatment failures occur in pa-
tients with any stage of disease. Identifying a prognostic in-
dicator might allow the identification of patients who are at* Correspondence: wskimsmc@skku.edu
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unless otherwise stated.risk of poor treatment outcomes. A recent study demon-
strated that the Glasgow Prognostic Score (GPS) has prog-
nostic value in ENKTL [4]. The GPS score is based on
measures of C-reactive protein (CRP) and albumin and
therefore reflects inflammatory activity [5]. Given that GPS
reflects both inflammation and ENKTL prognosis, tumor
aggressiveness may be associated with higher states of in-
flammation. Inflammatory cells frequently infiltrate ENKTL
tumors, and the majority of patients have clinical signs of
inflammation such as nasal tract inflammation. However,
any underlying mechanism by which inflammation may
contribute to poor ENKTL prognosis is still unknown.
The inflammatory milieu of a tumor’s microenviron-
ment is important in its growth and progression [6,7].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ence ENKTL aggressiveness through interaction with their
receptors in the tumor tissue. Chemokines are a family of
small signaling cytokines that recruit leukocytes to inflam-
matory sites and play a role in homeostatic activities (in-
cluding subsequent lymphocyte migration) [8,9]. On the
other hand, chemokines also contribute to tumor develop-
ment, growth, and metastasis [10,11]. Among various che-
mokines, C-X-C motif ligand 13 (CXCL13, also named as
B-cell attracting chemokine 1 (BCA-1)) is thought to play
an important pro-tumor role in colon, prostate, and breast
cancers through the interaction with its receptor, the C-X-
C chemokine receptor 5 (CXCR5) [12-14]. In particular, a
recent in vitro study with colorectal cancer cell linesTable 1 Clinical patient characteristics and their association w
Characteristics n




Performance status ECOG 0/1 56
ECOG ≥2 13
Ann Arbor stage I/II 29/11
III/IV 5/24
Serum LD Normal 30
Increased 39
B symptoms Absence 39
Presence 30
LN involvement Absence 40
Presence 29
Primary site Nasal 41
Extranasal 28
Bone marrow invasion No 56
Yes 13
Extranodal involvement 0/1 43
≥2 26









Abbreviations: PFS progression-free survival, OS overall survival, HR hazard ratio, ECO
node, EBV Epstein-Barr virus, IPI International Prognostic Index, NKPI NK/T-cell Lympreported the interaction of CXCL13 with CXCR5 activated
the phosphatidylinositol-3 kinase (PI3K)/AKT pathway
leading to migration and invasion of cancer cells [15]. In
NHL, a recent prospective study of inflammatory markers
demonstrated a significant association of serum CXCL13
with the risk of lymphoma supporting its role in the
lymphoma development [16]. Thus, considering its associ-
ation with lymphoma and the activation of PI3K/AKT
pathway, CXCL13 might have a positive correlation with
the aggressiveness of ENKTL because latent membrane
protein 1, an EBV oncoprotein could activate the PI3K/
AKT pathway in ENKTL [17]. If so, the elevated serum
level of CXCL13 could be an underlying mechanism for
the prognostic value of GPS in patients with ENKTL.ith survival outcomes
PFS OS
% HR P HR P
81
19 2.164 0.039 2.489 0.024
33
67 1.215 0.575 0.752 0.494
81
19 4.372 <0.001 3.736 0.001
42/16
7/35 1.935 <0.001 1.898 <0.001
44
56 3.124 0.002 2.456 0.026
56
44 2.634 0.004 2.310 0.027
58
42 2.236 0.017 3.258 0.002
59
41 4.092 <0.001 4.240 <0.001
81
19 6.591 <0.001 5.298 <0.001
62
38 2.948 0.001 2.616 0.011
61
39 4.111 <0.001 3.482 <0.001
48/16
24/12 2.482 <0.001 2.031 <0.001
26/12
29/33 2.162 <0.001 2.036 0.001
46
32
22 2.660 <0.001 3.052 <0.001
G Eastern Cooperative Oncology Group, LD lactate dehydrogenase, LN lymph
homa Prognostic Index, CRP C-reactive protein, GPS Glasgow Prognostic Score.
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analyzed their correlation with the GPS and survival out-
comes of ENKTL patients.
Patients and methods
Patients
Patients diagnosed with ENKTL from two prospective
cohort studies between September 2008 and December
2012 (first study: 2008–2011, NCT#00822731; second
ongoing study since 2012, NCT#01877109) were in-
cluded in this study. Written informed consent was ob-
tained from all patients. Clinical information, laboratory
results, and serum samples at diagnosis were obtained
from the cohort studies. All patients had received treat-
ment with curative intent. Treatments included concur-
rent chemoradiotherapy (CCRT) followed by systemic
chemotherapy for stage IE or IIE as previously reported
[2,18] or systemic chemotherapy with SMILE (steroid,
methotrexate, ifosfamide, L-asparaginase, and etoposide)Figure 1 The association of overall and progression-free survival with GPS
significant association with OS and PFS. (C, D) High CXCL13 levels are mor
survival than are lower levels.for stage III/IV [19,20]. The primary tumor site was deter-
mined based on the clinical presentation and included
nasal and extranasal sites, such as the skin, soft tissue, and
other organs. Three comprehensive prognostic models in-
cluding International Prognostic Index (IPI), NK Prognos-
tic Index (NKPI), and GPS were used to determine risk
group stratification. The GPS was calculated according to
serum CRP and albumin levels that were measured as part
of the clinical practice at diagnosis as described previously
[5,21]. Thus, patients with both an elevated CRP level
(>10 mg/L) and hypoalbuminemia (<35 g/L) received a
score of 2 whereas patients with elevated CRP or hypoal-
buminemia were allocated a score of 1. Patients with
neither of these abnormalities were given a score of 0.
The EBV DNA titer was measured upon diagnosis from
a whole blood sample, as previously reported [22].
The patients were dichotomized according to positive
and negative EBV DNA. Survival status was updated
at the time of analysis in December 2014. This studyand serum CXCL13. (A, B) Grouping by the GPS demonstrates a
e significantly associated with shorter overall and progression-free
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Samsung Medical Center.
Measurement of serum CXCL13 and CXCL13/CXCR5
immunohistochemistry
Serum samples were collected at diagnosis and stored
at −80°C until analysis. A Procarta cytokine profiling kit
(Panomics, CA, USA) was used to measure CXCL13
levels (three times) according to the manufacturer’s in-
structions. In order to evaluate the tissue expression of
CXCL13 and CXCR5, immunohistochemical analysis was
performed on formalin-fixed, paraffin-embedded, 4-μm
thick tissue sections. The tissue sections were deparaffi-
nized three times in xylene for a total of 15 min and were
then incubated with the primary monoclonal antibody
against CXCL13 (Clone 53610; MAB801; R&D Systems,
Minneapolis, MN, USA), and CXCR5 (Clone 51505; FAB190P;
R&D Systems, Minneapolis, MN, USA). Immunostaining
was performed using a BOND-MAX autoimmunostainerFigure 2 Tissue expression of CXCL13 and CXCR5, and its correlation with
staining (×400). (B) CXCR5 antibody stains the cytoplasm of ENKTL tumor ce
more patients with high CXCL13 in the GPS 2 group than in the GPS 0 or 1 g
disease than do patients with stage I/II (P < 0.05).(Leica Microsystems, Wetzlar, Germany) with BOND Polymer
Refine Detection (DS9800; Vision BioSystems, Melbourne,
Australia). Positivity for CXCL13 and CXCR5 was deter-
mined by comparing to the normal positive control from
the tonsillar germinal center. In every staining set, a nega-
tive control was included in which the primary antibodies
and probes were omitted.
Statistics
The chi-square test was used to analyze the association
between serum CXCL13 with clinical and laboratory pa-
rameters. The Kaplan-Meier method was used for univari-
ate analysis of survival outcomes. The survival outcomes
were compared with the log-rank test. Progression-free
survival (PFS) was defined as the time from the date of
diagnosis to the date of documented disease progression
or death. In contrast, the overall survival (OS) was mea-
sured from the date of diagnosis to the date of death
due to any cause. The OS was censored at the date ofGPS and stage. (A) Representative ENKTL case with negative CXCL13
lls and B-cells in a normal germinal center. (C) There were significantly
roups (P < 0.05). (D) More patients have high CXCL13 with stage III/IV
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was used in multivariate analysis for survival outcomes.




We analyzed 69 patients with a median age of 48 years
at diagnosis (range 17–75 years). Forty patients (58%)
had stages I or II, while 29 patients had stages III or IV
(42%). The most common primary tumor site was the
nasal tract (n = 41). Twenty-eight patients had extranasal
disease in areas including the skin and gastrointestinal
tract (Table 1). A circulating EBV DNA level was de-
tected in the whole blood of 27 patients, while 42 pa-
tients had no detectable EBV DNA. The majority of
patients (n = 44, 64%) were classified as being at low or
low-intermediate risk based on the IPI. Forty-three pa-
tients (62%) were classified into groups III or IV based
on their NKPI [23,24]. The median potential follow-up
was 47 months. A total of 38 patients had relapse or
progression. Thirty-four patients died, including twoTable 2 The association of CXCL13 and CCL3 with unfavorabl
CXCL13
Characteristics Low
Age (years) ≤60 32
>60 3
Ann Arbor stage I/II 30
III/IV 5
Serum LDH Normal 22
Increased 13
B symptoms Absence 25
Presence 10
LN involvement Absence 25
Presence 10
Primary site Nasal 29
Extranasal 6
Bone marrow invasion No 33
Yes 2
Extranodal involvement 0/1 29
≥2 6




NKPI Group I/II 22
Group III/IV 13
Abbreviations: LDH lactate dehydrogenase, LN lymph node, EBV Epstein-Barr virus, IP
GPS Glasgow Prognostic Score.cases of non-disease-related death. Univariate analysis of
the survival outcomes demonstrated that all clinical pa-
rameters (except sex) were significantly associated with
OS and PFS (Table 1). The GPS also demonstrated prog-
nostic relevance to OS and PFS in ENKTL patients, as
previously reported (Figure 1A, B) [4].
Serum CXCL13 and the GPS
The mean value of CXCL13 was 155.2 pg/mL (standard
deviation (SD): 406.7 pg/mL). There was only one pa-
tient with an undetectable CXCL13 level. The median
value was 29.1 pg/mL (range: 0.0–2517.6 pg/mL). Patients
were categorized into high (CXCL13 level >median value,
n = 34) and low (CXCL13 level ≤median value, n = 35)
CXCL13 groups. The high CXCL13 group had a higher
frequency of PFS events (27/34, 79%), including relapse/
progression or death, than did the low CXCL13 group
(13/35, 37%). Therefore, high levels of CXCL13 were sig-
nificantly associated with worse OS and PFS (Figure 1C, D).
Immunohistochemical staining for CXCL13 from 30 pa-
tients revealed that all of the tumor cells were negative for
CXCL13 (Figure 2A). The expression of CXCL13 was alsoe parameters
GPS
High P 0/1 2 P
24 48 8
10 0.034 6 7 0.005
10 37 3
24 <0.001 17 12 0.001
8 28 2
26 0.001 26 13 0.009
14 35 4
20 0.015 19 11 0.017
15 36 4
19 0.029 18 11 0.008
12 38 3
22 <0.001 16 12 0.001
23 49 7
11 0.006 5 8 0.001
14 38 5
20 <0.001 16 10 0.015
13 38 4
21 <0.001 16 11 0.006
14 42 2
20 <0.001 12 13 <0.001
4 24 2
30 <0.001 30 13 0.036
I International Prognostic Index, NKPI NK/T-cell Lymphoma Prognostic Index,
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mal lymphocytes adjacent tumor tissue showed positive
expression of CXCL13. In contrast, the tumor cells did ex-
press CXCR5 (Figure 2B). The serum CXCL13 was signifi-
cantly associated with risk stratification by the GPS. In
particular, all patients from the GPS 2 group had serum
levels of CXCL13 that are higher than the median value
(P < 0.001, Figure 2C). The mean serum level from the
GPS 2 group 2 (505.5 ± 778.3 pg/mL) was significantly
higher than that of the GPS 0 (50.2 ± 74.3 pg/mL) and
GPS 1 (69.0 5 ± 106.8 pg/mL) groups. High CXCL13 levels
were significantly associated with unfavorable prognostic
signs including advanced stage (III/IV, Figure 2D), extra-
nasal presentation, bone marrow invasion, and extranodal
involvement (Table 2). In addition, patients classified as
high-risk by the IPI or NKPI had significantly higher
serum levels of CXCL13 than did those at lower risk
(P < 0.001). EBV positivity was also significantly associated
with CXCL13 (P < 0.001). Like CXCL13, the GPS also
showed a significant association with unfavorable parame-
ters and high-risk groups of IPI and NKPI (Table 2).Figure 3 The subgroup analysis for the association of serum CXCL13 with
High CXCL13 levels are associated with lower overall survival among patien
fails to predict prognosis in patients with advanced disease and detectableHowever, serum levels of CXCL13 and GPS failed to show
independent prognostic values for OS and PFS in the
multivariate analysis with clinical parameters (P < 0.05,
data not shown).
Subgroup analysis
As grouping by the serum CXCL13 level and GPS was
not independently prognostic for survival outcomes, the
subgroup analysis was done according to tumor burden.
Patients were dichotomized into high and low tumor
burden based on stage and EBV DNA in blood. Elevated
CXCL13 levels were associated with poor OS in patients
with low tumor burden: those with non-detectable EBV
or stages I/II (Figure 3A, B). In contrast, in patients
with high tumor burden such as stage III/IV or detect-
able EBV, the serum CXCL13 was unable to predict
prognosis (Figure 3C, D). Grouping by the GPS also
showed a significant association with OS in patients
with low tumor burden similar to serum CXCL13 level
(Figure 4A, B). The association of the GPS with poor OS
was less significant in patients with stage III/IV andoverall survival based on stage and EBV DNA positivity in blood. (A, B)
ts with non-detectable EBV titers and stage I/II disease. (C, D) CXCL13
EBV titers.
Figure 4 The subgroup analysis for the association of GPS with overall survival based on stage and EBV DNA positivity in blood. (A, B) GPS is
associated with lower overall survival among patients with non-detectable EBV titers and stage I/II disease. (C, D) GPS shows a marginal
significance in patients with advanced disease and detectable EBV titers.
Kim et al. Journal of Hematology & Oncology  (2015) 8:49 Page 7 of 9detectable EBV DNA (Figure 4C, D). The lack of prog-
nostic significance of CXCL13 and GPS in patients with
high tumor burden might be related with a strong cor-
relation of elevated CXCL13 and GPS 2 with stage III/IV
and detectable EBV in this study (Table 2).
Discussion
Although a role for inflammation in cancer has long been
postulated in the mid-1800s, evidence supporting the as-
sociation of inflammation with cancer initiation, progres-
sion, and mortality has been gathered more recently. The
GPS based on CRP and serum albumin reflects the sys-
temic inflammatory response to cancer, and its proven
prognostic value in cancer patients augments the con-
tributory role of inflammation to tumor aggressiveness.
Our study demonstrated the GPS had a significant associ-
ation with OS and PFS in ENKTL patients inconsistent
with a previous finding [4]. Thus, patients who were given
a GPS of 2 showed worse OS and PFS than patients with
GPS 0 or 1 (Figure 1A, B). As we hypothesized CXCL13,an inflammatory chemokine might contribute to the prognos-
tic value of GPS, patients with an elevated serum CXCL13
level showed poor survival outcomes (Figure 1C, D).
Furthermore, an elevated serum CXCL13 level was
strongly correlated with the GPS, especially a score of 2
because all patients with GPS 2 showed an elevated level
of CXCL13 (Figure 2C).
CXCL13 is a follicular helper T-cell marker and a
known B-cell chemoattractant that plays a role in germi-
nal center formation [25,26]. Prior to this study, there
was no data about the prognostic value of serum CXCL13
in ENKTL as well as its relation with the GPS. Our study
demonstrated a significant association between serum
CXCL13 levels and a high-risk ENKTL classification ac-
cording to the GPS (P < 0.001, Figure 2C). Thus, our find-
ings suggested the increased serum levels of CXCL13
representing inflammatory activity might be associated
with unfavorable characteristics of ENKTL such as tumor
burden like previous studies reporting the contribution of
CXCL13 to solid tumor progression, that is, [6,7]. The
Kim et al. Journal of Hematology & Oncology  (2015) 8:49 Page 8 of 9immunohistochemistry with tumor tissue showed the
positive staining for CXCR5 and negative for CXCL13 on
lymphoma cells (Figure 2A, B). This result suggests that
the serum CXCL13 might be mostly coming from inflam-
matory cells, not tumor cells. Although there is no direct
data about the interaction of CXCL13 with CXCR5 in
lymphoma cells of ENKTL, a previous in vitro study with
AIDS-related non-Hodgkin lymphoma cell lines demon-
strated migration of lymphoma cells expressing CXCR5
toward CXCL13 [27]. Given that AIDS-related NHL is fre-
quently related with EBV infection, this CXCL13/CXCR5
interaction might be present in ENKTL like AIDS-related
NHL. Thus, the association of serum CXCL13 with stage
of ENKTL might be influenced by the major contributory
effect of CXCL13 to cell migration and invasion. However,
further studies are required to clarify the underlying
mechanism by which CXCL13/CXCR5 interaction is asso-
ciated with aggressiveness of ENKTL.
The grouping by serum levels of CXCL13 as well as the
GPS failed to show an independent prognostic value for
survival outcomes in this study unlike a previous study
demonstrating the superior independent prognostic value
of the GPS to IPI and NKPI in 164 patients with ENKTL
[4]. These findings might be related with a relatively smaller
number of patients in our study (n = 69) than the previous
study. However, the strong correlation of serum CXCL13
with the GPS as well as high tumor burden such as stage
and EBV DNA might influence their prognostic value in
the multivariate analysis. On the other hand, in the sub-
group analysis based on tumor burden, grouping by the
serum level of CXCL13 and GPS discriminated patients
with poor survival outcomes among those with stage I/II
disease and/or with non-detectable EBV DNA (Figures 3
and 4). Following this, patients with elevated CXCL13 levels
may be at a higher risk of treatment failure like patients
with GPS 2. Our study results were from ENKTL patients
that were registered in our prospective cohort study, and
all patients were treated with non-anthracycline-based
chemotherapy and/or concurrent chemoradiotherapy.
Considering the majority of prior studies were retrospect-
ive in nature and included patients who were treated with
anthracycline-based chemotherapy [1,28], our findings
may be relevant to patients who have been treated with
the current standard of care. The association of serum
CXCL13 with GPS and survival outcomes of ENKTL pa-
tients might suggest the possibility of CXCL13 as a prog-
nostic indicator and therapeutic target in patients with
ENKTL. Therefore, future studies with larger patient pop-
ulations should be warranted to confirm the prognostic
value of serum CXCL13.
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